ProtoKinetix, Inc. (NASDAQ:PKTX) CEO Clarence Edward Smith purchased 1,595,553 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was bought at an average cost of $0.04 per share, with a total value of $63,822.12. Following the completion of the transaction, the chief executive officer now directly owns 43,820,500 shares in the company, valued at approximately $1,752,820. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Clarence Edward Smith also recently made the following trade(s):

  • On Thursday, August 25th, Clarence Edward Smith purchased 90,753 shares of ProtoKinetix stock. The stock was bought at an average cost of $0.05 per share, with a total value of $4,537.65.
  • On Thursday, July 7th, Clarence Edward Smith purchased 90,000 shares of ProtoKinetix stock. The stock was bought at an average cost of $0.06 per share, with a total value of $5,400.00.
  • On Friday, July 1st, Clarence Edward Smith purchased 1,900,000 shares of ProtoKinetix stock. The stock was bought at an average cost of $0.04 per share, with a total value of $76,000.00.
  • On Friday, June 24th, Clarence Edward Smith purchased 175,000 shares of ProtoKinetix stock. The stock was bought at an average cost of $0.06 per share, with a total value of $10,500.00.

Shares of ProtoKinetix, Inc. (NASDAQ:PKTX) opened at 0.06 on Wednesday. ProtoKinetix, Inc. has a 52-week low of $0.02 and a 52-week high of $0.12. The company has a 50-day moving average price of $0.05 and a 200-day moving average price of $0.06. The stock’s market capitalization is $13.36 million.

About ProtoKinetix

ProtoKinetix, Incorporated is a research and development-stage bio-technology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins, known as AAGPs. AFGP is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures.

5 Day Chart for NASDAQ:PKTX

Receive News & Ratings for ProtoKinetix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProtoKinetix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.